about
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Guidelines for the diagnosis and treatment of malignant pleural mesotheliomaEfficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.Optimizing the erythromycin breath test for use in cancer patients.Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography.Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trialsCirculating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisCytokine profiling of docetaxel-resistant castration-resistant prostate cancer.Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature.Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours.Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape.Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.No improvement in lung cancer care: the management of lung cancer in 1996 and 2002 in New South Wales.PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.Diethylstilbestrol revisited in advanced breast cancer management.Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre.Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer.Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.
P50
Q27852408-ED1A1E06-06C8-4614-B98F-36320A251C5BQ27853120-DE9B37DE-7D54-476C-90E9-EF8F82C8C3B9Q28394028-9861A347-8C8C-4CD7-B0F8-B2DD090C2393Q30486440-E175AC95-49DB-4880-90B9-7C863CA95138Q30657007-BABA0369-FBC1-46A4-86D2-03EB0639E7D4Q30663239-5C58D21E-13AF-4ED0-9BBA-2DBB7BE78E4FQ30888735-ED1D3B89-B9F3-44FA-9426-225C6B729ED3Q31033454-607E8131-5FB2-4856-91E8-13A062EEE918Q31160116-41F37A7D-ED71-4018-986F-2EF1AB81C82FQ33332750-1FD039A5-1726-4146-B8CB-DEA3FC821241Q33371606-DAB96677-4CE6-4B8E-9C18-FFAF1F00DDC1Q33391857-31FC2503-5166-4F70-BED8-2AF848533ED6Q33395621-A3D6A576-9A48-472F-AABD-CEF756CB1C7FQ33397078-73D3678F-D7C2-4FF0-8E74-E18097C96A31Q33436415-F5413DC8-6ADC-4D33-82F5-6DB373071246Q33613644-579BB891-06FC-42FC-8BE0-A32C4B65539EQ33913964-28C73965-07BF-449B-A768-78BF98120789Q34047897-3212FCCD-EF47-4CF5-903A-F5AFF3F932A9Q35475443-D02402BE-8728-435B-A7E4-ACFD70B0EAD2Q35865760-B8DD41E5-41B7-43F7-AD5C-41B51F5B085BQ35977837-7B337B95-43EF-4162-862B-80F43DD6B868Q36611703-E4E0144C-4FF8-48E4-B04C-33D25EC56CD8Q37496421-730EFCA7-9173-4FE2-9163-76BD7E8D7080Q37659109-27FF956C-74CE-4961-905E-205D0CFAF72CQ38199766-C6B7BD8E-2E7B-4D9F-9D44-923FECBD3724Q38273671-BA13CF6E-1B94-4F85-8539-D3F5651F559BQ38382659-A341BAD5-9EBF-46D5-B5C0-3A8436E61A95Q38451808-4E17CE58-3580-435A-935C-9E1A2B90F591Q38699598-D756273C-BEFA-4CB9-A90A-B99A8CFCEB9AQ38718563-DE227863-A29D-41BF-B95C-F0483C841546Q38809376-54B45926-24D1-4129-94F3-BAAF1BCCF668Q38935346-A3A707CA-22B8-4AE6-8E70-6FF49E46B4BEQ38945133-61205C35-67A5-40D4-ACAA-884617768E50Q39378286-D38B82BB-FD20-4D37-9ACC-AB5B271EFD20Q39470816-8765947F-EEE4-4375-9414-EABA3B1759A4Q39519904-5926E08F-B502-458A-9084-5FFA221867F8Q39796352-A65D13DD-DC0F-4C5F-B35D-2F2DEBAFE865Q39952539-4EA18983-7444-43C1-939A-72A4975E337AQ40098978-CD06A3D1-FDDD-4A45-AB45-D015744E48A2Q40341641-845A4596-2B7F-4E86-8705-F4BB13270CE2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Boyer
@ast
M Boyer
@en
M Boyer
@es
M Boyer
@nl
type
label
M Boyer
@ast
M Boyer
@en
M Boyer
@es
M Boyer
@nl
prefLabel
M Boyer
@ast
M Boyer
@en
M Boyer
@es
M Boyer
@nl
P214
P106
P214
P31
P496
0000-0002-0452-2987
P7859
viaf-105966772